On ECHEMI
Home > Drugs > Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd.
Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd.
  • Founded in:

    2011-11-15
  • Country:

    China China
  • Address:

    No. 10 Dingshan Road, Binjiang Development Zone, Jiangyin City
  • Tax NO.:

    91320281585574148F
  • Registered Funds:

    261 million yuan
  • Website:

  • Email:

Related Drugs
Lidocaine Hydrochloride Injection (Solvent)
The main ingredient of this product is lidocaine hydrochloride. Its chemical name is N-(dichloroxylyl)-2-(diethylamino)acetamide hydrochloride monohydrate.
Name Description Content CAS NO. Registered Holders
Lidocaine hydrochloride

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, it can promote the outflow of K in myocardial cells, reduce the autonomy of the myocardium, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of the heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

More

This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, it can promote the outflow of K in myocardial cells, reduce the autonomy of the myocardium, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of the heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.

6108-05-0 45
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.